GSA Capital Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,837,491
| Closed | -$983K | – | 2173 |
|
|
2024
Q4 | $983K | Buy |
1,837,491
+820,857
| +81% | +$572K | 0.07% | 423 |
|
|
2024
Q3 | $1.79M | Buy |
1,016,634
+817,050
| +409% | +$1.14M | 0.14% | 159 |
|
|
2024
Q2 | $234K | Buy |
+199,584
| New | +$499K | 0.02% | 1399 |
|
|
2022
Q4 | – | Sell |
-30,856
| Closed | -$205K | – | 1992 |
|
|
2022
Q3 | $205K | Sell |
30,856
-11,400
| -27% | -$70.2K | 0.03% | 1214 |
|
|
2022
Q2 | $205K | Sell |
42,256
-23,273
| -36% | -$142K | 0.03% | 1059 |
|
|
2022
Q1 | $613K | Sell |
65,529
-55,842
| -46% | -$555K | 0.08% | 412 |
|
|
2021
Q4 | $1.44M | Sell |
121,371
-7,037
| -5% | -$81.3K | 0.18% | 84 |
|
|
2021
Q3 | $1.46M | Buy |
+128,408
| New | +$1.77M | 0.15% | 136 |
|
|
2020
Q1 | – | Sell |
-11,844
| Closed | -$102K | – | 1664 |
|
|
2019
Q4 | $102K | Buy |
+11,844
| New | +$66.5K | 0.01% | 1340 |
|
|
2018
Q3 | – | Sell |
-4,975
| Closed | -$141K | – | 1971 |
|
|
2018
Q2 | $141K | Buy |
+4,975
| New | +$110K | 0.01% | 1574 |
|
|
2018
Q1 | – | Sell |
-5,125
| Closed | -$167K | – | 1871 |
|
|
2017
Q4 | $167K | Buy |
+5,125
| New | +$138K | 0.01% | 1443 |
|
GSA Capital Partners's MRNS Position: Q1 2025 in Review
GSA Capital Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 1,837,491 shares — an estimated $983K sold.
GSA Capital Partners first reported a position in MRNS in Q4 2017 and held it in 11 quarters. The position peaked at $1.79M in Q3 2024. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- GSA Capital Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- GSA Capital Partners sold 1,837,491 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $983K.
- GSA Capital Partners first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 11 quarters.
- GSA Capital Partners's Marinus Pharmaceuticals, Inc position peaked at $1.79M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.